ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRCAmgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting Share XESMO21: First combo data with Amgen’s Lumakras hit the mark in CRChttps://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/
